| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 6, 2005
Accepted on September 21, 2005
Department of Endocrinology (H.F.E.-M., J.I.B.-C., F.A.-B. and J.S.) and Molecular Genetics (J.L.S.M.), Hospital Ramón y Cajal, Madrid, Spain
* To whom correspondence should be addressed. E-mail: hescobarm.hrc{at}salud.madrid.org.
Context The polycystic ovary syndrome (PCOS) is frequently associated with obesity. However, there are very few data about PCOS in morbid obesity, especially with regards to its evolution after bariatric surgery.
Objective To evaluate the response of PCOS to the sustained and marked weight loss achieved by bariatric surgery in morbidly obese women.
Design Longitudinal prospective nonrandomized evaluation
Settings Academic hospital.
Patients Thirty-six consecutive premenopausal women submitted to bariatric surgery were screened for PCOS, which was present in seventeen.
Interventions Bariatric surgery
Main Outcome Measures Hyperandrogenism, menstrual function and insulin resistance were estimated before and at least six months after bariatric surgery in twelve patients with PCOS.
Results Weight loss (41 ± 9 kg after 12 ± 5 months) was paralleled by a decrease in the hirsutism score (from 9.5 ± 6.8 to 4.9 ± 4.2, P = 0.001), total (69 ± 32 to 42 ± 19 ng/dL, P < 0.02) and free testosterone (from 1.6 ± 0.7 to 0.6 ± 0.3 ng/dL, P < 0.005), androstendione (from 4.1 ± 1.5 to 3.0 ± 0.9 ng/mL, P < 0.02) and dehydroepiandrosterone-sulfate (from 2000 ± 1125 to 1353 ± 759 ng/mL, P < 0.005), amelioration of insulin resistance estimated by homeostasis model assessment (from 6.0 ± 3.0 to 1.6 ± 1.0, P < 0.001) and the restoration of regular menstrual cycles and/or ovulation in all the patients.
Conclusions The polycystic ovary syndrome is a frequent finding in women with morbid obesity, and may resolve after weight loss induced by bariatric surgery.
This article has been cited by other articles:
 |
|
 |
|
  M. Corton, J. I. Botella-Carretero, J. A. Lopez, E. Camafeita, J. L. San Millan, H. F. Escobar-Morreale, and B. Peral Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry Hum. Reprod., March 1, 2008; 23(3): 651 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Barbieri Clomiphene Versus Metformin for Ovulation Induction in Polycystic Ovary Syndrome: The Winner Is .... J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3399 - 3401. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mohlig, M. O Weickert, E. Ghadamgadai, A. Machlitt, B. Pfuller, A. M Arafat, A. F H Pfeiffer, and C. Schofl Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women Eur. J. Endocrinol., August 1, 2007; 157(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
